ZEISS Metrology Shop provides planning security

ZEISS Metrology Shop brings it all together.

Nocebo – the evil twin that makes you feel worse

The placebo effect is well known in healthcare, but not so its opposite: nocebo. “The effect is small, but it can have major repercussions,” says Uppsala resear...

An easy way to handle microtiter plate stacks

Do you want to automate handling of microtiter plates.? Have a look at a very simple solution on how to handle them.

ZEISS presents the "Quality Innovation Days"

The digital event for metrology and software.

Beta-blockers are often given unnecessarily, a study finds – “This will affect future practice”

Patients who have suffered a minor heart attack do not benefit from beta-blockers, according to a major new study that may change guidelines for cardiac care.

Automated dispensing of a viscous hydrogel

A suitable solution developed for UPM Biomedicals In the Festo LifeTech Application Center we tested a setup for UPM Biomedicals for the automatic dispensing of...

Tungt namn föreslås ta över klubban i Sobi

Valberedningen i särläkemedelsbolaget Sobi föreslår att David Meek utses till ny styrelseordförande vid en extra bolagsstämma i december.

Krönika: Collaboration across borders

From Valneva to the CEO position at NorthX – “I saw it as a great opportunity”

A new cell therapy for leukaemia, a vaccine in tablet form against cholera, and a proprietary mRNA line with the potential capacity to supply the entire Nordic ...

Anna Törner: ”Orphan Designation – the "petite robe noire" of drug development”

It is easy to cling to various regulatory incentives, like orphan designation, and other expedited pathways, without understanding what they truly mean or wheth...

Standardisation in automation

B. Braun Melsungen had a great idea and implemented it throughout the plant. Production for infusion solutions was to be largely standardised. B. Braun hoped th...

Miljonregn över ”excellenta” inkubatorer

Det står nu klart vilka svenska inkubatorer som klassas som excellenta och får dela på totalt nästan 400 miljoner kronor i stöd från innovationsmyndigheten Vinn...

Storbolag i gräl om hiv-läkemedel

En träta om påstått vilseförande marknadsföring av hiv-läkemedel mellan läkemedelsbolagen Gilead och Glaxo Smith Kline (GSK) har nu avgjorts – till den senares fördel.

Don't miss ZEISS Quality Innovation Days

Digital event April 15-19, 2024.

Åsa Uppströmer ny vd för Pharma Relations

Pharma Relations har anställt Åsa Uppströmer som ny vd.

”Information security must become part of the Swedish life science strategy”

Sweden needs knowledge security to stand strong in the global competition, writes Björn Ursing in an opinion article.

Swedish Healthtech Company 1928 Pushing Forward

The full service analytics platform is expanding the business.

Digital Temperature Sensors from ZEISS

New Metrology Expert Tip video.

Venom from the deathstalker carries radiopharmaceuticals to the brain

In order to target cancerous brain tumours with radionuclides, the problematic blood-brain barrier must first be crossed. Life Science Sweden has visited a KI r...

To build trust, one must be able to say “I don’t know” – whether human or AI

Will AI strengthen or break down trust? It depends on whether we can understand and accept its limitations, and our own, writes Sarah Lidé in a column.

Raised millions to develop a treatment for ´butterfly children´

Fragile as a butterfly’s wing – that’s how people living with Epidermolysis Bullosa are usually described. The Lund-based company Xinnate recently raised SEK 10...

Swedish and Ukrainian Medical Product Agencies sign an agreement

The Directors-General of the Swedish and Ukrainian Medical Products Agencies have signed a cooperation agreement.

Major investment in women’s health – for a more equal healthcare system

”The regional differences need to decrease and the long-term supply of midwives and other professions needs to be secured,” write Acko Ankarberg Johansson and D...

Fuskanklagat pharmabolag lägger ner alzheimerprojekt

Amerikanska Cassava Sciences avbryter utvecklingen av sin läkemedelskandidat inom Alzheimers sjukdom efter misslyckande i en fas III-studie